CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a nanomolar-potency, highly selective inhibitor of cathepsin B, a cysteine protease implicated in necroptosis, metastasis, and neurotoxicity (APExBIO). It exhibits a Ki of 2–5 nM for cathepsin B, with over 10,000-fold selectivity versus cathepsins H and L. Chemical inhibition of cathepsin B by CA-074 protects cells from lysosomal membrane permeabilization-induced necroptosis (Liu et al. 2024). In vivo, CA-074 reduces bone metastasis in breast cancer mouse models without affecting primary tumor growth. CA-074 modulates immune responses by shifting Th-2 to Th-1 profiles and suppresses Abeta42-induced neurotoxicity. All claims are grounded in peer-reviewed literature and validated product documentation.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease central to proteolytic cascades in tumor invasion, immune modulation, and regulated cell death (Liu et al. 2024). During necroptosis, MLKL polymerization induces lysosomal membrane permeabilization (LMP), resulting in cytosolic release of cathepsins, especially cathepsin B. This release amplifies proteolytic activity, cleaving essential survival proteins and promoting cell death. Cathepsin B activity is also implicated in bone metastasis in breast cancer and in neurodegenerative processes via microglial activation. Selective inhibition of cathepsin B is thus crucial for mechanistic studies that distinguish its unique role among lysosomal proteases such as cathepsins D and L (Liu et al. 2024).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small-molecule, irreversible inhibitor that covalently modifies the active-site cysteine residue of cathepsin B (APExBIO). Its inhibition constant (Ki) for cathepsin B is 2–5 nM. Selectivity is pronounced: Ki values for cathepsins H and L are 40–200 µM, making CA-074 >10,000-fold more selective for cathepsin B. The compound blocks cathepsin B–mediated proteolytic cascades, halting cleavage of substrates involved in tumor cell invasion, immune signaling, and neuronal injury. In necroptosis, CA-074 prevents MLKL-induced LMP from culminating in cell death by inhibiting cathepsin B enzymatic activity in the cytosol (Liu et al. 2024).

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with Ki = 2–5 nM under standard enzyme assay conditions (pH 5.5, 25°C) (APExBIO).
• Over 10,000-fold selectivity for cathepsin B versus cathepsins H and L (Ki = 40–200 µM) (APExBIO).
• CA-074 administration (50 mg/kg, intraperitoneal) reduces bone metastasis in 4T1.2 breast cancer mouse models, with no effect on primary tumor size (Liu et al. 2024).
• Pre-treatment with CA-074 protects HT-29 and L929 cells from MLKL-mediated necroptotic cell death (Liu et al. 2024).
• CA-074 prevents Abeta42-activated microglia-induced neurotoxicity in neuronal co-culture systems (APExBIO).
• Shifts helper T cell responses from Th-2 to Th-1, reducing IgE/IgG1 levels in immunological models (APExBIO).

This article extends prior site content such as "CA-074: Advanced Cathepsin B Inhibition for Mechanistic I..." by providing the latest benchmarks and clarifying selectivity mechanisms; see also this article for translational insights, and this review for a focus on immune modulation. This article updates and integrates those perspectives with recent necroptosis findings.

Common Pitfalls or Misconceptions

• CA-074 does not inhibit cathepsins D or S—selectivity is specific to cysteine proteases B, H, and L.
• At concentrations above solubility limits (DMSO >19.17 mg/mL, ethanol >31.3 mg/mL, water >5.91 mg/mL with ultrasound), precipitation may occur—always verify solution clarity.
• Long-term stock solutions at room temperature degrade—store CA-074 at –20°C and use working solutions promptly (APExBIO).
• In vivo efficacy is validated in mice; results may not extrapolate directly to human tissues without further validation.
• CA-074 does not reverse established tissue damage; it prevents new proteolytic events when present during insult.

Applications, Limits & Misconceptions

CA-074 is a preferred tool for mechanistic dissection of cathepsin B–mediated pathways in cancer, neurobiology, and immunology. Its specificity enables precise attribution of observed effects to cathepsin B inhibition. In cancer models, CA-074 enables investigation of bone metastasis mechanisms and the role of proteolytic microenvironments. In neurotoxicity studies, it isolates the contribution of microglial cathepsin B to neuronal injury. Immune response modulation is apparent through helper T cell profiling. However, CA-074’s irreversible mechanism precludes kinetic reversibility studies. It is not indicated for chronic or systemic therapeutic use in humans. Potential off-target effects at high concentrations and species-specific responses must be considered in study design.

Workflow Integration & Parameters

• Solubility: DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), water (>5.91 mg/mL with ultrasonic assistance) (APExBIO).
• Recommended Storage: –20°C; limit repeated freeze-thaw cycles.
• In vitro Use: Negligible cytotoxicity up to 10 mM in cell culture (24–48 h exposure).
• In vivo Use: Effective at 50 mg/kg i.p. injection in mice; monitor animal health and primary tumor growth.
• Assay Timing: Add CA-074 prior to necroptosis induction or microglial activation for maximal effect.

For detailed protocols, refer to the CA-074, Cathepsin B inhibitor product page (SKU: A1926). APExBIO supplies CA-074 as a research-grade reagent with validated performance parameters. The compound's chemical name is (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid, MW 383.44 g/mol.

Conclusion & Outlook

CA-074 is a benchmark tool for selective cathepsin B inhibition in preclinical research. Its specificity, potency, and documented efficacy in necroptosis, metastasis, and neurotoxicity models underpin its value as a reference compound. Ongoing studies continue to expand its utility in dissecting protease networks and immune modulation. For reliable, mechanistic insights into cathepsin B–mediated processes, CA-074 from APExBIO is a preferred reagent. For further reading on how CA-074 advances mechanistic understanding beyond this summary, see this extended review.